Zobrazeno 1 - 10
of 158
pro vyhledávání: '"Jingshan, Shen"'
Autor:
Hongjian Qin, Zijian Han, Emmanuel Mintah Bonku, Haiguo Sun, Abdullajon Odilov, Fuqiang Zhu, Safomuddin Abduahadi, Weiliang Zhu, Jingshan Shen, Haji A. Aisa
Publikováno v:
Communications Chemistry, Vol 7, Iss 1, Pp 1-9 (2024)
Abstract Amides are important intermediates in organic chemistry and the pharmaceutical industry, but their low reactivity requires catalysts and/or severe reaction conditions for esterification. Here, a novel approach was devised to convert amides i
Externí odkaz:
https://doaj.org/article/2d0296056171457d831e32f0f08b6e31
Autor:
Emmanuel Mintah Bonku, Hongjian Qin, Abdullajon Odilov, Safomuddin Abduahadi, Samuel Desta Guma, Feipu Yang, Xinglong Xing, Xukun Wang, Jingshan Shen
Publikováno v:
Heliyon, Vol 10, Iss 9, Pp e29559- (2024)
This article delineates the systematic identification, synthesis, and impurity control methods used during the manufacturing process development of tecovirimat, an antiviral drug that treats monkeypox. Critical impurities were synthesized, and their
Externí odkaz:
https://doaj.org/article/9fe4477831ed46f093e9e3d4841dd56e
Autor:
Xiangrui Jiang, Haixia Su, Weijuan Shang, Feng Zhou, Yan Zhang, Wenfeng Zhao, Qiumeng Zhang, Hang Xie, Lei Jiang, Tianqing Nie, Feipu Yang, Muya Xiong, Xiaoxing Huang, Minjun Li, Ping Chen, Shaoping Peng, Gengfu Xiao, Hualiang Jiang, Renhong Tang, Leike Zhang, Jingshan Shen, Yechun Xu
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report
Externí odkaz:
https://doaj.org/article/a28e5c09138247129c790be1234763fd
Autor:
Yumin Zhang, Yuan Sun, Yuanchao Xie, Weijuan Shang, Zhen Wang, Hualiang Jiang, Jingshan Shen, Gengfu Xiao, Leike Zhang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract During the ongoing pandemic, providing treatment consisting of effective, low-cost oral antiviral drugs at an early stage of SARS-CoV-2 infection has been a priority for controlling COVID-19. Although Paxlovid and molnupiravir have received
Externí odkaz:
https://doaj.org/article/891dbeaa644d412cbba032b38ed92b99
Autor:
Zhijian Xu, Danrong Shi, Jian-Bao Han, Yun Ling, Xiangrui Jiang, Xiangyun Lu, Chuan Li, Likun Gong, Guangbo Ge, Yani Zhang, Yi Zang, Tian-Zhang Song, Xiao-Li Feng, Ren-Rong Tian, Jia Ji, Miaojin Zhu, Nanping Wu, Chunhui Wu, Zhen Wang, Yechun Xu, Cheng Peng, Min Zheng, Junling Yang, Feifei Du, Junliang Wu, Peipei Wang, Jingshan Shen, Jianliang Zhang, Yong-Tang Zheng, Hangping Yao, Weiliang Zhu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-8 (2023)
Abstract Effective drugs with broad spectrum safety profile to all people are highly expected to combat COVID-19 caused by SARS-CoV-2. Here we report that nelfinavir, an FDA approved drug for the treatment of HIV infection, is effective against SARS-
Externí odkaz:
https://doaj.org/article/cbeb9c93ea5442cba5846201420e2c42
Autor:
Rulei Yang, Yiran Liu, Ning Yang, Tian Zhang, Jiazhen Hou, Zongyan He, Yutong Wang, Xujie Sun, Jingshan Shen, Hualiang Jiang, Yuanchao Xie, Tianqun Lang
Publikováno v:
Pharmaceutics, Vol 16, Iss 4, p 570 (2024)
Colorectal cancer (CRC) ranks as the third most prevalent global malignancy, marked by significant metastasis and post-surgical recurrence, posing formidable challenges to treatment efficacy. The integration of oligonucleotides with chemotherapeutic
Externí odkaz:
https://doaj.org/article/85a8bb3da5b9472b84b7427288e00dc0
Autor:
Shavkat I. Salikhov, Ibrokhim Y. Abdurakhmonov, Yuliya I. Oshchepkova, Jamolitdin F. Ziyavitdinov, Nodir Sh. Berdiev, Haji Akber Aisa, Jingshan Shen, Yechun Xu, H. Eric Xu, Xiangrui Jiang, Leike Zhang, Natalia L. Vypova, Dilshod Sh. Allaberganov, Nigora A. Tagayalieva, Erkin I. Musabaev, Gulnara A. Ibadova, Ilxom B. Rajabov, Lyubov M. Lokteva
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Previously, from the tannic sumac plant (Rhus coriaria), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposin
Externí odkaz:
https://doaj.org/article/8dfb66c2f40449c8a848cd89e71ebd15
Autor:
Fuxiang Wang, Wen Xiao, Yimin Tang, Mengli Cao, Dan Shu, Tetsuya Asakawa, Yechun Xu, Xiangrui Jiang, Leike Zhang, Wei Wang, Jianxing Tang, Yuansheng Huang, Yang Yang, Yumei Yang, Renhong Tang, Jingshan Shen, Hongzhou Lu
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 38, Iss , Pp 100835- (2023)
Summary: Background: SIM0417 (SSD8432) is an orally administered coronavirus main proteinase (3CLpro) inhibitor with potential anti-SARS-CoV-2 activity. This study aimed to evaluate the efficacy and safety of SIM0417 plus ritonavir (a pharmacokinetic
Externí odkaz:
https://doaj.org/article/e5cbb5b842784fa9b314a8ee813b9849
Autor:
Ruxue Zhang, Yumin Zhang, Wei Zheng, Weijuan Shang, Yan Wu, Ning Li, Jun Xiong, Hualiang Jiang, Jingshan Shen, Gengfu Xiao, Yuanchao Xie, Leike Zhang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 7, Iss 1, Pp 1-3 (2022)
Externí odkaz:
https://doaj.org/article/75805ed61f39466baf41743349518a57
Autor:
Haixia Su, Sheng Yao, Wenfeng Zhao, Yumin Zhang, Jia Liu, Qiang Shao, Qingxing Wang, Minjun Li, Hang Xie, Weijuan Shang, Changqiang Ke, Lu Feng, Xiangrui Jiang, Jingshan Shen, Gengfu Xiao, Hualiang Jiang, Leike Zhang, Yang Ye, Yechun Xu
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
SARS-CoV-2 3CL protease (3CLpro) is essential for coronavirus replication and of great interest as an antiviral drug target. Here, the authors show that the naturally occurring flavonoid myricetin is a non-peptidomimetic and covalent inhibitor of 3CL
Externí odkaz:
https://doaj.org/article/ff68234682c746f3aa209aef3785fbf8